April 15, 2021 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Agilent Completes Acquisition of Resolution Bioscience, Expands Role in Fast-growing NGS Market for Precision Oncology

SANTA CLARA, Calif., April 15, 2021  Agilent Technologies, Inc. (NYSE: A) today announced it has completed the acquisition of Resolution Bioscience, a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. Resolution Bioscience complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further... Read more

April 14, 2021 Atomic Spectroscopy Chromatography Life Science Tools Liq. Handling & Robotics Mass Spectrometry Molecular Spectroscopy PR/Corporate

Agilent Named One of Singapore’s Best Employers

Company rises in rank from last year SINGAPORE, April 14, 2021  Agilent Technologies Inc. (NYSE: A) today announced that Agilent Singapore has been recognized as one of Singapore’s Best Employers in 2021 for the second year-in-a-row by The Straits Times, a leading Singapore-based newspaper. Specifically, Agilent is ranked among the top 100 companies and fifth out... Read more

March 15, 2021 Chromatography Product Launch

Agilent Announces the 8697 Headspace Sampler with Integrated Intelligence

Integrated technology provides a true system approach to gas chromatography  SANTA CLARA, Calif., March 15, 2021  Agilent Technologies Inc. (NYSE: A) today introduced the Agilent 8697 Headspace Sampler, the first headspace sampler with integrated gas chromatography communication. It marks the expansion of intelligence capability that was first launched with the Agilent Intuvo 9000 GC System in... Read more

March 9, 2021 Chromatography Life Science Tools Mass Spectrometry PR/Corporate

Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer

SANTA CLARA, Calif., March 09, 2021  Agilent Technologies Inc. (NYSE: A), today announced that Dr. Katharine (Kate) Knobil is joining Agilent as the company’s chief medical officer (CMO). The chief medical officer at Agilent is a newly created position designed to advise, lead, and elevate the company’s presence in the health-care industry. As Agilent’s first... Read more

March 9, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection

Kit expands Agilent’s product portfolio aimed at COVID-19 detection SANTA CLARA, Calif., March 09, 2021  Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and... Read more

March 2, 2021 Clinical Research/Diagn. M&A, Partnerships

Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics

SANTA CLARA, Calif., March 02, 2021  Highlights: Resolution Bioscience is a fast-growing, innovative leader in next-generation sequencing (NGS)-based oncology solutions. Combination brings together Resolution Bioscience’s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent’s leadership in tissue-based companion diagnostics and global commercial and regulatory scale. Furthers Agilent’s participation in fast-growing NGS technologies for precision... Read more

February 22, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)

Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif., February 22, 2021  Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3... Read more

February 18, 2021 Clinical Research/Diagn. Life Science Tools Product Launch

Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies

Kit marks first of multiple planned for 2021 aimed at COVID-19  SANTA CLARA, Calif., February 18, 2021  Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which... Read more

February 17, 2021 Cell Analysis Tools Product Launch

Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis

Enhanced data quality, easier workflow, and more versatile analytics using fewer cell numbers SANTA CLARA, Calif., February 17, 2021  Agilent Technologies Inc. (NYSE: A) today introduced the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyzer for improved immune cell metabolic analysis. Immunology and disease researchers are increasingly using rare, ex vivo, and genetically engineered... Read more

February 1, 2021 Chromatography Licensing, IP, and Legal

Agilent Wins Trade Secret and Patent Infringement Litigation

J&X Technologies to pay Agilent more than $1.25 million in damages for “willful and malicious” theft of Agilent trade secrets  SANTA CLARA, Calif., February 01, 2021  Agilent Technologies Inc. (NYSE: A) today announced it has won a judgement in federal court for patent infringement and trade secret misappropriation against Shanghai-based J&X Technologies. The court victory... Read more